Patritumab Deruxtecan(HER3-DXd;MK-1022)用于经铂类化疗和免疫治疗后非小细胞肺癌患者
这项研究评估了HER3导向抗体药物偶联物HER3-DXd在经铂类化疗和免疫检查点抑制剂治疗后进展的晚期非小细胞肺癌患者中的疗效与安全性,每3周静脉给予5.6 mg/kg。47例患者中确认客观缓解率为27.7%,中位缓解持续时间8.1个月,中位无进展生存期5.5个月,中位总生存期15.2个月。研究药物相关≥3级治疗中出现不良事件发生率为51.1%,治疗相关间质性肺病5例(10.6%),均为1或2级。
要点
- HER3-DXd 5.6 mg/kg每3周静脉给药,在47例经治晚期NSCLC中确认客观缓解率为27.7%。
- 中位无进展生存期5.5个月,中位总生存期15.2个月,中位缓解持续时间8.1个月。
- 研究药物相关≥3级治疗中出现不良事件发生率为51.1%,治疗相关间质性肺病5例(10.6%)。
核心结论
- HER3-DXd在经重度治疗的EGFR突变NSCLC患者中先前报告的疗效和安全性,在其他NSCLC亚型患者中也被观察到,值得进一步临床评估。
研究设计与样本
- 开放标签研究,纳入47例晚期鳞状或非鳞状NSCLC患者,无常见EGFR激活突变,既往治疗后进展,包括铂类化疗、免疫检查点抑制剂和靶向治疗(对已知可操作基因组改变的患者)。
主要发现
- 确认客观缓解率为27.7%(95% CI,15.6%至42.6%),中位缓解持续时间为8.1(95% CI,4.2至不可评估)个月。
- 中位无进展生存期为5.5(95% CI,4.0至11.2)个月,中位总生存期为15.2(95% CI,10.8至17.7)个月。
- 在携带已识别驱动基因组改变和无此类基因组特征的患者中观察到相似的疗效。
- 研究药物相关≥3级治疗中出现不良事件发生于51.1%的患者,其中12.8%为严重事件(无死亡相关事件)。
- 经裁定的治疗相关间质性肺病发生于5例患者(10.6%;均为1级或2级)。
关键数值与推荐
- HER3-DXd 5.6 mg/kg静脉给药,每3周一次。
- 确认客观缓解率27.7%(95% CI,15.6%至42.6%)。
- 中位缓解持续时间8.1(95% CI,4.2至不可评估)个月。
- 中位无进展生存期5.5(95% CI,4.0至11.2)个月,中位总生存期15.2(95% CI,10.8至17.7)个月。
- 研究药物相关≥3级治疗中出现不良事件发生率51.1%,严重事件12.8%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出值得进一步临床评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patritumab deruxtecan (HER3-DXd; MK-1022) is an investigational HER3-directed antibody-drug conjugate composed of a human immunoglobulin G1 monoclonal antibody to HER3 (patritumab) covalently linked via a stable tetrapeptide-based cleavable linker to a topoisomerase I inhibitor payload that has shown durable antitumor activity in previously treated patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC). We extend these observations to patients with advanced NSCLC with other/no identified driver genomic alterations. METHODS: Patients with advanced squamous or nonsquamous NSCLC without a common EGFR-activating mutation whose disease had progressed on previous therapies including platinum-based chemotherapy, immune checkpoint inhibitors, and targeted therapy (for patients with known actionable genomic alterations) received HER3-DXd 5.6 mg/kg intravenously once every 3 weeks. The primary end point was confirmed objective response rate (cORR). RESULTS: Forty-seven patients were treated with HER3-DXd (median treatment duration, 4.2 [range, 0.7-19.8] months). The cORR was 27.7% (95% CI, 15.6% to 42.6%), and the median duration of response was 8.1 (95% CI, 4.2 to not evaluable) months. The median progression-free survival was 5.5 (95% CI, 4.0 to 11.2) months, and the median overall survival was 15.2 (95% CI, 10.8 to 17.7) months. Similar efficacy was observed in patients with NSCLC harboring identified driver genomic alterations and in those without such genomic features. The rate of study drug discontinuation associated with treatment-emergent adverse events (TEAEs) was 12.8%. Study drug-related grade ≥3 TEAEs occurred in 51.1% of patients and were serious in 12.8% (none were associated with death). Adjudicated treatment-related interstitial lung disease occurred in five patients (10.6%; all grade 1 or 2). CONCLUSION: The previously reported efficacy and safety of HER3-DXd in heavily pretreated patients with EGFR-mutated NSCLC are also observed in those with other NSCLC subtypes and warrant further clinical evaluation.
引用
- Steuer CE, Hayashi H, Su WC, et al. Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy. J Clin Oncol. 2025. PMID: 40554742. doi:10.1200/JCO-24-02744
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。